Welcome to our dedicated page for Burning Rock Biotech news (Ticker: BNR), a resource for investors and traders seeking the latest updates and insights on Burning Rock Biotech stock.
Burning Rock Biotech Limited (NASDAQ: BNR) is a cancer diagnostics company focused on applying next generation sequencing (NGS) technology to precision oncology. The BNR news stream features company announcements on therapy selection testing, early cancer detection programs, pharmaceutical collaborations and financial performance.
In its press releases, Burning Rock regularly reports quarterly and annual financial results, with details on revenues from its central laboratory business, in-hospital business and pharma research and development services. These updates often include commentary on gross margins, operating expenses, and the mix of revenue from Mainland China and overseas customers.
News about Burning Rock also covers scientific and clinical milestones. The company highlights study results on circulating tumor DNA (ctDNA), minimal residual disease (MRD) monitoring, and multi-cancer early detection, presented at major conferences and in journals. It reports on the progress of products such as OncoScreen™ Plus, the CanCatch® Custom MRD assay, and multi-omics early detection tests that have advanced into clinical validation.
Another key theme in BNR news is companion diagnostics and pharmaceutical partnerships. Burning Rock has announced CDx collaborations, regulatory approvals such as the OncoGuide™ OncoScreen™ Plus CDx System in Japan, and an NMPA-approved NGS-based CDx for EGFR exon 20 insertion mutation in lung cancer. Corporate governance items, including annual general meeting results and auditor appointments, also appear in the company’s news flow.
Investors and healthcare professionals can use this news page to follow Burning Rock’s disclosures on its precision oncology platform, business segment trends, regulatory developments and scientific achievements related to BNR stock.
Burning Rock Biotech (NASDAQ: BNR) reported Q3 2024 financial results with total revenues of RMB128.6 million (US$18.3 million), a 0.8% increase year-over-year. The company saw a 17% growth in in-hospital business revenue to RMB63.8 million, while central laboratory revenue decreased 25.2% to RMB40.0 million. Pharma R&D services revenue increased 27.1% to RMB24.9 million.
The company's gross profit increased 6.9% to RMB91.8 million, with gross margin improving to 71.4% from 67.4%. Operating expenses decreased 50.7% to RMB130.4 million due to reduced share-based compensation and improved efficiency. Net loss narrowed to RMB35.7 million from RMB175.0 million in the previous year. Cash and equivalents stood at RMB498.2 million as of September 30, 2024.
Burning Rock Biotech (NASDAQ: BNR) has announced its Annual General Meeting (AGM) scheduled for December 31, 2024, at 10:00 a.m. local time at the company's Shanghai office. The AGM will address three key proposals: ratification of Ernst & Young Hua Ming LLP as auditor for FY2024, re-election of Yusheng Han and Gang Lu as directors, and authorization for directors to implement these resolutions. The record date is set for December 4, 2024, for shareholders and ADS holders to determine voting eligibility. The board fully supports these proposals and recommends shareholders vote in favor.
Burning Rock Biotech (NASDAQ: BNR) and Dizal have jointly announced the approval of the first co-developed NGS-based companion diagnostic (CDx) for lung cancer by China's National Medical Products Administration (NMPA). This CDx is designed for EGFR exon 20 insertion mutation (exon20ins) for sunvozertinib, marking a significant milestone in precision oncology.
The approval is the result of simultaneous development of Burning Rock's LungCure CDx and Dizal's sunvozertinib therapy, offering an innovative precision treatment solution for non-small cell lung cancer patients with EGFR exon20ins. This collaboration sets a new benchmark for concurrent development of companion diagnostics for anti-tumor drugs and positions Burning Rock to drive global CDx development for pharmaceutical companies.
Burning Rock Biotech (NASDAQ: BNR) announced significant changes in its management and Board of Directors on September 27, 2024. Mr. Leo Li has resigned from his positions as a director on the company's Board and as the Chief Financial Officer, effective immediately. Mr. Li confirmed that his resignation was due to personal reasons and not related to any disagreements with the company.
In light of this change, Ms. Xiaozhi Hu, senior director in finance, will take charge of financial operations, reporting, and related matters. Ms. Hu, who joined Burning Rock in May 2014, will report directly to Mr. Yusheng Han, the chairman of the board and CEO. Mr. Han expressed gratitude for Mr. Li's contributions, particularly during the company's IPO and subsequent business development projects.
Burning Rock Biotech (NASDAQ: BNR, LSE: BNR) reported its Q2 2024 financial results. Total revenues decreased by 7.3% to RMB135.5 million (US$18.7 million) compared to the same period in 2023. The in-hospital segment showed 11.2% growth, while the central laboratory business experienced a 26.4% decline. Gross profit decreased by 5.0% to RMB95.4 million (US$13.1 million), with an improved gross margin of 70.4%. Operating expenses decreased by 12.5% due to efficiency measures. Net loss narrowed to RMB108.0 million (US$14.9 million). The company's cash position stood at RMB533.0 million (US$73.3 million) as of June 30, 2024.
Burning Rock Biotech has announced its intention to delist its American Depositary Shares (ADSs) from the London Stock Exchange (LSE) and cancel their listing on the Official List of the UK Financial Conduct Authority. The company cites sustained low trading volume and liquidity of its ADSs on the LSE as the primary reason for this decision, along with the costs associated with maintaining the listing. The delisting is expected to take effect on or around September 18, 2024. Importantly, Burning Rock's ADSs will continue to trade on the Nasdaq Global Market after the LSE delisting.
Burning Rock Biotech has regained compliance with NASDAQ's minimum bid price requirement. The company received a notification from NASDAQ on May 30, 2024, confirming the compliance. Previously, on December 29, 2023, Burning Rock was notified of non-compliance due to its American depositary shares (ADSs) trading below $1.00 for 30 consecutive business days. To address this, the company adjusted the ratio of its ADSs from 1:1 to 1:10, effective May 15, 2024. This adjustment helped maintain a closing bid price of $1.00 or higher for 10 consecutive business days, leading to the regaining of compliance.
Burning Rock Biotech (NASDAQ: BNR) has announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) in China. This partnership aims to enhance diagnostic methods and enable better treatment choices for cancer patients. The collaboration will focus on developing CDx products for Bayer's precision cancer therapies. Burning Rock's CEO, Mr. Han, emphasized the commitment to global development in cancer diagnosis and treatment, aiming to set high standards and provide more effective treatment options through this partnership.
Burning Rock Biotech (NASDAQ: BNR, LSE: BNR), a precision oncology firm using next-generation sequencing (NGS) technology, announced its Q1 2024 financial results. Total revenues for the quarter were RMB125.6 million (US$17.4 million), an 11.9% decrease year-over-year (YoY). The in-hospital segment grew by 11.3%, while central laboratory and pharma research services declined by 23.0% and 29.3% respectively. Gross profit dropped by 13.2% to RMB85.7 million (US$11.9 million), and the gross margin fell to 68.2%. Operating expenses decreased by 26.4% to RMB211.5 million (US$29.3 million), driven by improved efficiency. Net loss narrowed to RMB121.5 million (US$16.8 million) from RMB185.3 million YoY. The company expects to break even by the end of 2024 based on non-GAAP measures. Cash and equivalents stood at RMB572.7 million (US$79.3 million). Additionally, the company relocated its headquarters to Guangzhou.
Burning Rock Biotech (NASDAQ: BNR; LSE: BNR) will release its unaudited financial results for Q1 2024 on May 29, 2024, before the U.S. market opens.
The company will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss the results. Interested participants should register in advance and join the call 15 minutes early.
A live and archived webcast of the call will be available on the company’s investor relations website for 12 months.
Visit the investor relations website on May 29, 2024, to access the earnings release.